The IPP Knockout A-549 Polyclonal Cells product provides a heterogeneous population of human A-549 lung adenocarcinoma cells engineered with CRISPR/Cas9 to disrupt the IPP gene. This polyclonal knockout model avoids clonal selection artifacts and serves as a robust loss-of-function tool for probing IPP biology in an epithelial carcinoma context. The use of a polyclonal population captures the full spectrum of gene-editing outcomes and phenotypic heterogeneity, enabling more physiologically relevant cellular studies.
The A-549 parental cell line was established from a lung adenocarcinoma of a 58-year-old Caucasian male and harbors an oncogenic KRAS G12S mutation. Widely utilized as an alveolar type II pneumocyte model, A-549 cells are instrumental in non-small cell lung cancer research, respiratory biology, and drug development. Their epithelial character and defined genetic background make them a standard platform for investigating tumor cell migration, adhesion, and signaling.
IPP is an actin-binding kelch family protein that bridges cytoskeletal regulation and mRNA processing. It is activated downstream of Rho family GTPases (RhoA, Rac1, Cdc42) and upstream receptors EGFR and integrins. IPP interacts with actin and the splicing factor SRSF1, coordinating actin filament dynamics with alternative splicing. Key downstream modules include RhoA/ROCK/LIMK/cofilin, FAK and paxillin at focal adhesions, and SRSF1-mediated splicing. Thus, IPP influences both cytoskeletal mechanics and post-transcriptional gene regulation.
Knockout of IPP in the A-549 background is expected to impair actin reorganization, reduce focal adhesion turnover, and attenuate SRSF1-dependent splicing, which collectively disrupt cell migration and invasion capacities. Given the KRAS-driven oncogenic signaling of these cells, the IPP knockout model is particularly valuable for dissecting how cytoskeletal effectors translate oncogenic inputs into pro-metastatic behaviors. It also provides a system to explore the cross-talk between actin dynamics and mRNA processing in lung adenocarcinoma progression.
This model is suited for migration and invasion assays (wound healing, Transwell), adhesion assays, and Rho GTPase activation profiling. Western blotting and immunofluorescence can confirm IPP loss and assess FAK/paxillin phosphorylation or F-actin organization. RNA-seq or RT-qPCR detects splicing changes, while drug testing with cisplatin or other chemotherapeutics probes the role of IPP in therapeutic response. For technical details or to discuss custom applications, please contact Ascent Research.
